IPM Take
GLP-1 medicines are not self-implementing. ENDO 2026 showed that the clinical promise is large, but the delivery model is fragile. Patients stop and restart therapy. Physical activity may fall when muscle protection should be a priority. Some patients need more behavioural support to respond well. Others, especially older adults or people taking multiple blood pressure medicines, may need closer monitoring. The next policy fight is not whether GLP-1s work. It is whether health systems can fund, monitor and support them as long-term cardiometabolic care, not short-term weight-loss transactions.
Executive Summary
ENDO 2026, held in Chicago, brought several GLP-1 findings that shift the conversation from headline weight loss to real-world delivery. One insurance-records study of more than 60,000 Americans with type 2 diabetes found that about 4 in 10 patients stopped GLP-1 therapy within the first year and nearly 6 in 10 stopped by two years, although more than half restarted within a year. Another study using NIH All of Us data linked to Fitbit records found that adults with obesity reduced their daily steps and moderate-to-vigorous activity after starting GLP-1 therapy. A real-world tirzepatide analysis suggested that response varies by clinical and behavioural factors, including goal setting and previous structured diet attempts. Separately, Northwestern Medicine researchers reported increased hypotension-related events among patients already taking multiple antihypertensive medicines after GLP-1 initiation. Together, the findings point to one signal: GLP-1 care needs structured follow-up, not just prescribing capacity.
Why it matters
- HTA bodies: Need to assess not only drug efficacy, but the service model required for sustained benefit, including monitoring, persistence support and behavioural interventions.
- Payers: Coverage decisions should account for discontinuation, restart patterns, side-effect management, blood pressure monitoring and support services, not only medicine cost.
- Clinicians: GLP-1 prescribing increasingly requires medication review, physical activity counselling, realistic expectations and follow-up for patients with complex cardiometabolic risk.
- Patients: GLP-1s may offer major benefits, but patients need clear information on side effects, activity, muscle protection, treatment breaks and when to seek clinical advice.
- Industry / innovation partners: The next competitive edge may be evidence on adherence, patient support, safety monitoring and real-world outcomes, not only weight-loss percentages.
ENDO 2026 did not kill the GLP-1 story.
It made it more serious.
For the past few years, the public conversation has treated GLP-1 medicines as if the main question were simple: how much weight can they help people lose?
That question still matters.
But the findings presented at ENDO 2026 in Chicago suggest that the real challenge is shifting from efficacy to implementation. GLP-1s are becoming long-term cardiometabolic medicines used across obesity, type 2 diabetes, cardiovascular risk and kidney-risk populations. That means they need systems around them.
Without that, the “revolution” becomes fragile.
One of the clearest signals came from a study of more than 60,000 Americans with type 2 diabetes. Researchers found that about 4 in 10 patients stopped GLP-1 therapy within the first year. By two years, nearly 6 in 10 had stopped.
That is not a small leakage problem.
It is a pathway problem.
The same study found that many patients restarted therapy. More than half of those who stopped restarted within one year, and nearly two-thirds restarted within two years. That suggests GLP-1 use in the real world is not simply “on” or “off”. It is start, stop, restart, pause, switch and try again.
That matters because consistent use is what supports long-term cardiometabolic protection.
If people stop early because of side effects, cost, access barriers or weak follow-up, then the health system loses part of the benefit it expected to buy. The study also found that Medicaid or Medicare users, Black patients and those experiencing gastrointestinal side effects were more likely to discontinue within a year. Patients were less likely to stop if their first GLP-1 prescription came from an endocrinologist.
That is the equity signal.
Access to the medicine is not enough if support is uneven.
Another ENDO 2026 study challenged a different assumption: that weight loss naturally leads to more movement.
Using data from the NIH All of Us Research Program linked with Fitbit activity data, researchers studied adults with obesity who started GLP-1 therapy. Among those with sufficient wearable-device data, average daily steps fell from 5,047 to 4,487 after starting treatment. Moderate-to-vigorous physical activity fell from 28 to 22 minutes per day.
That matters because GLP-1 medicines can reduce lean mass as well as fat mass. Preserving muscle requires physical activity, resistance training and nutrition support. If activity falls during treatment, the long-term health picture becomes more complicated.
The message is not anti-GLP-1.
It is anti-fantasy.
A prescription alone does not build muscle, maintain function or protect long-term cardiometabolic health. Patients need structured support, especially if GLP-1 therapy changes appetite, energy intake and body composition.
A third ENDO 2026 study added a personalised medicine angle.
A large real-world analysis of people using tirzepatide found that weight-loss response varied by clinical and behavioural factors. Women, people without pre-existing conditions such as type 2 diabetes and hypertension, and those who had previously set a weight goal were among the strongest predictors of total weight loss.
That should make policymakers uncomfortable.
If behavioural support helps determine outcomes, then reimbursing only the medicine may be a false economy. Patients with motivational barriers or complex comorbidity may need more support, not less. Otherwise, people with the highest cardiometabolic risk may be the least likely to achieve the full benefit.
ENDO 2026 also brought a safety and monitoring signal from the cardiovascular side.
Northwestern Medicine researchers analysed more than 42,000 adults taking at least two classes of blood pressure medication who started semaglutide, tirzepatide or liraglutide. Low blood pressure-related events, including dizziness, fainting, falls, low systolic blood pressure and hypotension diagnoses, increased after GLP-1 initiation. The risk was especially relevant among older adults and people with diabetes.
The point is not that GLP-1s are unsafe for these patients.
The point is that they are powerful enough to require active medication review.
If a patient loses weight, improves glucose control and experiences lower blood pressure, old medication regimens may become too strong. Antihypertensive therapy may need to be reviewed and de-escalated. That requires clinician oversight, not a remote prescription with no follow-up.
Taken together, these findings change the policy conversation.
GLP-1s are often discussed as expensive medicines. They are also infrastructure tests.
Can health systems identify who is most likely to benefit?
Can they support patients who are likely to discontinue?
Can they monitor side effects and blood pressure?
Can they integrate nutrition, physical activity and muscle protection?
Can they avoid leaving lower-income and minority patients with weaker follow-up?
Can payers reimburse a care pathway, not just a product?
These questions matter because GLP-1s are moving into wider cardiometabolic medicine. They are no longer only diabetes drugs or obesity drugs. They are becoming part of cardiovascular prevention, kidney-risk management, sleep apnoea care and long-term metabolic disease strategy.
That makes the stakes much higher.
If health systems treat GLP-1s as short-term weight-loss injections, they will underdeliver. If they treat them as long-term cardiometabolic interventions requiring monitoring and support, they may reshape prevention.
ENDO 2026 did not show that GLP-1s are overhyped.
It showed that the hype is too shallow.
The real story is not whether these medicines work.
It is whether systems are ready to make them work for the people who need them most.
